REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced new data to be featured at the ...
Synthetic Data Generation by Artificial Intelligence to Accelerate Research and Precision Medicine in Hematology Three models for yearly time series predictions were built: autoregressive integrated ...
Analysis of the first subset of linked SEER patient data demonstrates DecisionDx®-Melanoma testing was associated with improved overall survival rates compared to untested patients DecisionDx-Melanoma ...
The probability of overall survival after 1, 5, and 10 years was predicted by a nomogram model, which found that worse Surveillance, Epidemiology, and End Results (SEER) stage was associated with ...
Medication burden, characterized by polypharmacy and suboptimal treatment adherence, is a predictor for acute care use among ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window BALTIMORE -- The ...
Seer, Inc. will announce Q2 2025 financial results on August 6, 2025, with a webcast at 1:30 PM PT. Seer, Inc. announced that it will release its financial results for the second quarter of 2025 on ...
REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced new data to be featured at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback